We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

7 hedge funds and large institutions have $209K invested in Aptevo Therapeutics in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

10% less capital invested

Capital invested by funds: $231K → $209K (-$22.5K)

30% less funds holding

Funds holding: 10 → 7 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$164K
2
HF
HRT Financial
New York
+$92.1K
3
JP Morgan Chase
JP Morgan Chase
New York
+$37.4K
4
Morgan Stanley
Morgan Stanley
New York
+$31.6K
5
UBS Group
UBS Group
Switzerland
+$5.75K

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$168K
2
Citadel Advisors
Citadel Advisors
Florida
-$20.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$7.85K
4
Renaissance Technologies
Renaissance Technologies
New York
-$6.58K
5
TSS
Two Sigma Securities
New York
-$5.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$93K +$164K +57 +1,900%
HF
2
HRT Financial
New York
$53K +$92.1K +32 +1,600%
JP Morgan Chase
3
JP Morgan Chase
New York
$19.5K +$37.4K +13 New
DP
4
Diadema Partners
New Jersey
$17.5K +$31.6K +11 New
Morgan Stanley
5
Morgan Stanley
New York
$16.9K +$31.6K +11 New
TRCT
6
Tower Research Capital (TRC)
New York
$4.68K +$2.88K +1 +50%
UBS Group
7
UBS Group
Switzerland
$3.38K +$5.75K +2 New
SS
8
SBI Securities
Japan
$565 – – –
BlackRock
9
BlackRock
New York
$103 – – –
CFFP
10
Center for Financial Planning
Michigan
$22 – – –
Bank of America
11
Bank of America
North Carolina
$17 – – –
DB
12
Danske Bank
Denmark
$4 – – –
Osaic Holdings
13
Osaic Holdings
Arizona
$4 – – –
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
– -$168K -70 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$20.1K -8 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$7.85K -3 Closed
Renaissance Technologies
17
Renaissance Technologies
New York
– -$6.58K -3 Closed
TSS
18
Two Sigma Securities
New York
– -$5.04K -2 Closed
Jane Street
19
Jane Street
New York
– -$3.1K -1 Closed
Two Sigma Investments
20
Two Sigma Investments
New York
– -$2.55K -1 Closed
PNC Financial Services Group
21
PNC Financial Services Group
Pennsylvania
– -$1 – –
Wells Fargo
22
Wells Fargo
California
– -$6 – –

APVO Hedge Fund Activity: Q4 2024 in Review

7 of the 7,594 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2024, worth a combined $209K — down 9.7% from $231K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of APVO and 4 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Virtu Financial, adding an estimated $164K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $168K sold.

  • 7 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2024, down from 10 in Q3 2024.
  • Funds reported $209K of Aptevo Therapeutics stock for Q4 2024, down 9.7% quarter-over-quarter.
  • 4 funds opened new Aptevo Therapeutics positions in Q4 2024 and 7 closed out, a net change of -3 holders.
  • The largest Aptevo Therapeutics buyer in Q4 2024 was Virtu Financial, an estimated $164K added.
  • The largest Aptevo Therapeutics seller in Q4 2024 was Hudson Bay Capital Management, an estimated $168K sold.

Based on aggregated 13F filings for Q4 2024.